Literature DB >> 21512411

Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.

Deng-Chyang Wu1, Ping-I Hsu, Hui-Hwa Tseng, Feng-Woei Tsay, Kwok-Hung Lai, Chao-Hung Kuo, Sheng-Wen Wang, Angela Chen.   

Abstract

Antibiotic resistance to amoxicillin in second-line eradication therapy for Helicobacter pylori infection is much less frequent than resistance to metronidazole. We conducted a randomized, controlled study to compare the efficacies of standard quadruple rescue therapy and a new therapy with amoxicillin replacing metronidazole for patients failing first-line eradication treatment. We randomly assigned 120 patients who failed H. pylori eradication using a proton pump inhibitor plus clarithromycin and amoxicillin to undergo a 1-week rescue therapy with esomeprazole, bismuth subcitrate, and tetracycline plus either metronidazole (EBTM group, n = 62) or amoxicillin (EBTA group, n = 58). We used follow-up endoscopy 8 weeks after the end of treatment to assess the treatment response. We also examined and analyzed antibiotic resistances and CYP2C19 genotypes. Intention-to-treat analysis demonstrated that the EBTA group had a significantly lower eradication rate than the EBTM group (62% vs. 81%, respectively, p = 0.02). Per-protocol analysis showed similar results (64% vs. 83%, p = 0.01). However, the EBTA group had less frequency of adverse events than the EBTM group (19% vs. 44%, p < 0.01). Both groups had good drug compliance (both 97%). Antibiotic susceptibility tests showed that the frequency of amoxicillin-resistant strains was much less than that of metronidazole-resistant strains (0% vs. 54%, respectively), and there were no significant differences between H. pylori eradication rates and antibiotic resistances. In conclusion, EBTA quadruple therapy demonstrated a lower eradication rate than standard EBTM therapy in second-line rescue treatment. The discrepancy between in vitro antibiotic susceptibility and in vivo eradication response is probably due to drug interactions between combined antibiotics or some unknown causes, and should not be neglected in H. pylori therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512411     DOI: 10.1097/MD.0b013e31821c9d1c

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  18 in total

1.  Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Authors:  J P Gisbert; A Perez-Aisa; L Rodrigo; J Molina-Infante; I Modolell; F Bermejo; M Castro-Fernández; R Antón; B Sacristán; A Cosme; J Barrio; Y Harb; M Gonzalez-Barcenas; M Fernandez-Bermejo; A Algaba; A C Marín; A G McNicholl
Journal:  Dig Dis Sci       Date:  2013-10-15       Impact factor: 3.199

Review 2.  Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection?

Authors:  Zhi-Fa Lv; Fu-Cai Wang; Hui-Lie Zheng; Ben Wang; Yong Xie; Xiao-Jiang Zhou; Nong-Hua Lv
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 3.  A new look at anti-Helicobacter pylori therapy.

Authors:  Seng-Kee Chuah; Feng-Woei Tsay; Ping-I Hsu; Deng-Chyang Wu
Journal:  World J Gastroenterol       Date:  2011-09-21       Impact factor: 5.742

Review 4.  CYP2C19 polymorphism influences Helicobacter pylori eradication.

Authors:  Chao-Hung Kuo; Chien-Yu Lu; Hsiang-Yao Shih; Chung-Jung Liu; Meng-Chieh Wu; Huang-Ming Hu; Wen-Hung Hsu; Fang-Jung Yu; Deng-Chyang Wu; Fu-Chen Kuo
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

5.  Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.

Authors:  I-Ting Wu; Seng-Kee Chuah; Chen-Hsiang Lee; Chih-Ming Liang; Lung-Sheng Lu; Yuan-Hung Kuo; Yi-Hao Yen; Ming-Luen Hu; Yeh-Pin Chou; Shih-Cheng Yang; Chung-Mou Kuo; Chung-Huang Kuo; Chun-Chih Chien; Yu-Shao Chiang; Shue-Shian Chiou; Tsung-Hui Hu; Wei-Chen Tai
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

6.  Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.

Authors:  Ping-I Hsu; Deng-Chyang Wu; Wen-Chi Chen; Hui-Hwa Tseng; Hsien-Chung Yu; Huay-Min Wang; Sung-Shuo Kao; Kwok-Hung Lai; Angela Chen; Feng-Woei Tsay
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

7.  Update on triple therapy for eradication of Helicobacter pylori: current status of the art.

Authors:  Riccardo Urgesi; Rossella Cianci; Maria Elena Riccioni
Journal:  Clin Exp Gastroenterol       Date:  2012-09-17

8.  Rescue Therapy for Helicobacter pylori Infection 2012.

Authors:  Javier P Gisbert
Journal:  Gastroenterol Res Pract       Date:  2012-02-28       Impact factor: 2.260

9.  Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.

Authors:  Hye-Kyung Jung; Seung Joo Kang; Yong Chan Lee; Hyo-Joon Yang; Seon-Young Park; Cheol Min Shin; Sung Eun Kim; Hyun Chul Lim; Jie-Hyun Kim; Su Youn Nam; Woon Geon Shin; Jae Myung Park; Il Ju Choi; Jae Gyu Kim; Miyoung Choi
Journal:  Korean J Intern Med       Date:  2021-06-08       Impact factor: 2.884

10.  Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis.

Authors:  Shailja C Shah; Adam Tepler; Cecilia P Chung; Giovanni Suarez; Richard M Peek; Adriana Hung; Christianne Roumie; Neeraj Narula
Journal:  Gastroenterology       Date:  2021-08-03       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.